Target Validation Information | |||||
---|---|---|---|---|---|
Target ID | T22118 | ||||
Target Name | Dopamine D1 receptor | ||||
Target Type | Successful |
||||
Drug Potency against Target | (R,S)-homoaromaline hydrochloride | Drug Info | IC50 = 15400 nM | ||
Ro-21-7767 | Drug Info | IC50 = 955 nM | [533759] | ||
FLUMEZAPINE | Drug Info | IC50 = 20 nM | [533515] | ||
SB-271046 | Drug Info | Ki = 120 nM | [529191] | ||
FLUTROLINE | Drug Info | IC50 = 14 nM | [533512] | ||
Phenyltoloxamine | Drug Info | Ki = 343 nM | [527160] | ||
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one | Drug Info | Ki < 1000 nM | [531079] | ||
1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine | Drug Info | Ki = 7600 nM | [528099] | ||
(R)-2,11-Diaminoaporphine | Drug Info | Ki = 2920 nM | [529541] | ||
(R)-11-Amino-2-methoxyaporphine | Drug Info | Ki = 78 nM | [529541] | ||
FALCARINDIOL | Drug Info | Ki = 192 nM | [529238] | ||
1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol | Drug Info | Ki = 5.4 nM | [529371] | ||
1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine | Drug Info | IC50 = 1500 nM | [533570] | ||
3-bromoboldine | Drug Info | IC50 = 66 nM | [525759] | ||
NORSTEPHALAGINE | Drug Info | IC50 = 4800 nM | [528616] | ||
1,2,3,7,12,12a-hexahydro-1-aza-pleiaden-5-ol | Drug Info | Ki = 3700 nM | [528616] | ||
3-Iodoboldine | Drug Info | IC50 = 3 nM | [525759] | ||
6-(2-Dipropylamino-ethyl)-biphenyl-2,3-diol | Drug Info | Ki = 1940 nM | [533481] | ||
9-Aminomethyl-9H-fluorene-3,4-diol | Drug Info | Ki = 380 nM | [533481] | ||
11-Hexanoyloxy-N-n-propylnoraporphine | Drug Info | Ki = 10 nM | [529686] | ||
(R)-(-)-N-ethyl-2-methoxy-11-hydroxynoraporphine | Drug Info | Ki = 130 nM | [529289] | ||
(R)-(-)-N-propyl-2-methoxy-11-hydroxynoraporphine | Drug Info | Ki = 1690 nM | [529289] | ||
1-Aminomethyl-isochroman-5,6-diol | Drug Info | Ki = 1030 nM | [530404] | ||
A-70108 | Drug Info | Ki = 1.6 nM | [530404] | ||
PUKATEINE | Drug Info | IC50 = 400 nM | [528616] | ||
N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide | Drug Info | Ki = 6800 nM | [529734] | ||
6-(2-Amino-ethyl)-biphenyl-2,3,4'-triol | Drug Info | Ki = 1650 nM | [533481] | ||
(R)-(-)-2-methoxy-11-hydroxyaporphine | Drug Info | Ki = 46 nM | [529289] | ||
R-N-PROPYLNORAPOMORPHINE | Drug Info | Ki = 3410 nM | [529289] | ||
BOLDINE | Drug Info | IC50 = 400 nM | [525759] | ||
BP-897 | Drug Info | Ki = 636 nM | [527264] | ||
Ecopipam | Drug Info | Ki = 1.9 nM | [533332] | ||
(+/-)-nantenine | Drug Info | Ki = 895 nM | [530558] | ||
(+)-BUTACLAMOL | Drug Info | Ki = 1.8 nM | [525773] | ||
MELOSMINE | Drug Info | IC50 = 12500 nM | [528616] | ||
1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine | Drug Info | Ki = 379 nM | [527160] | ||
6-(2-Dipropylamino-ethyl)-biphenyl-2,3,4'-triol | Drug Info | Ki = 1740 nM | [533481] | ||
MCL-516 | Drug Info | Ki = 1480 nM | [529850] | ||
9-Aminomethyl-9H-fluorene-2,5,6-triol | Drug Info | Ki = 43 nM | [533481] | ||
SCH-24518 | Drug Info | Ki = 2.35 nM | [533416] | ||
IBZM | Drug Info | Ki = 12000 nM | [529011] | ||
(-)-(1S,1'R)-O,O-dimethylgrisbine hydrochloride | Drug Info | IC50 = 5640 nM | |||
SCH-12679 | Drug Info | IC50 = 491 nM | [534738] | ||
(S,S)-oxandrine hydrochloride | Drug Info | IC50 = 11100 nM | |||
ISOLOXAPINE | Drug Info | IC50 = 2480 nM | [533577] | ||
TEPA (possesses cytotoxic activity) | Drug Info | IC50 = 430 nM | [534719] | ||
(R)-(-)-10-methyl-11-hydroxyaporphine | Drug Info | Ki = 9650 nM | [528876] | ||
6-(2-Amino-ethyl)-biphenyl-2,3-diol | Drug Info | Ki = 1500 nM | [533481] | ||
Fenoldopam | Drug Info | Ki = 15.0 nM | [552866] | ||
(S)APOMORPHINE | Drug Info | Ki = 2980 nM | [530342] | ||
2-methoxyapomorphine | Drug Info | Ki = 2600 nM | [529349] | ||
(R)-(-)-2-methoxy-N-npropylnorapomorphine | Drug Info | Ki = 6450 nM | [529289] | ||
(R)-(-)-11-hydroxy-N-n-propylnoraporphine | Drug Info | Ki = 699 nM | [529289] | ||
1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine | Drug Info | Ki = 11000 nM | [525629] | ||
1,2-Bis-[R-(-)-apomorphine-2'-oxy]ethane | Drug Info | Ki = 5200 nM | [529349] | ||
2-{[R-(-)-Apomorphine-2'-oxy]ethoxy}-ethanol | Drug Info | Ki = 7600 nM | [529349] | ||
(+)-(1R,1'S)-berbamunine hydrochloride | Drug Info | IC50 = 1040 nM | |||
N-(4-Propylaminobutyl)-4-biphenylcarboxamide | Drug Info | Ki = 7300 nM | [529734] | ||
QUINPIROLE | Drug Info | Ki = 63 nM | [527714] | ||
4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine | Drug Info | Ki = 201 nM | [527160] | ||
1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine | Drug Info | Ki = 10000 nM | [525629] | ||
(R)-(+)-coclaurine | Drug Info | IC50 = 240 nM | [534656] | ||
3,8-dibromoboldine | Drug Info | IC50 = 206 nM | [525759] | ||
1-Aminomethyl-3-phenyl-isochroman-5,6-diol | Drug Info | Ki = 7200 nM | [530404] | ||
(S)-BULBOCAPNINE | Drug Info | IC50 = 740 nM | [528616] | ||
GLAUCINE | Drug Info | Ki = 2900 nM | [528616] | ||
1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol | Drug Info | Ki = 10800 nM | [528616] | ||
3-Chloroboldine | Drug Info | IC50 = 81 nM | [525759] | ||
[R-(-)-Apomorphine-2-yl]-(2'-hydroxy-ethyl)ether | Drug Info | Ki = 5300 nM | [529349] | ||
2-Methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline | Drug Info | IC50 = 27 nM | [533578] | ||
Pergolide | Drug Info | EC50 = 1040 nM | [553248] | ||
ISOCLOZAPINE | Drug Info | IC50 = 11 nM | [534532] | ||
11-Butyryloxy-N-n-propylnoraporphine | Drug Info | Ki = 12 nM | [529686] | ||
11-Heptanoyloxy-N-n-propylnoraporphine | Drug Info | Ki = 31 nM | [529686] | ||
11-valeryloxynoraporphine | Drug Info | Ki = 23 nM | [529686] | ||
11-Propionyloxy-N-n-propylnoraporphine | Drug Info | Ki = 18 nM | [529686] | ||
1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine | Drug Info | Ki = 113 nM | [527160] | ||
STEPHOLIDINE | Drug Info | Ki = 5.9 nM | [530374] | ||
1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine | Drug Info | Ki = 33.7 nM | [527160] | ||
Etoloxamine | Drug Info | Ki = 1959 nM | [527160] | ||
1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine | Drug Info | Ki = 14000 nM | [525629] | ||
SK&F-89626 | Drug Info | IC50 = 120 nM | [530341] | ||
(+)-(1R,1'S)-thaligrisine hydrochloride | Drug Info | IC50 = 5600 nM | |||
Action against Disease Model | Fenoldopam | EC50 in relaxation of preconstricted mesenteric/l uMbar/renal artery: 3600nM/6200nM/3400nM | [553130] | Drug Info | |
Methylergonovine | The h uMan histamine H1 receptor (H1R) is an important, well characterized target for the development of antagonists to treat allergic conditions. Many neuropsychiatric drugs are known to potently antagonize the H1R, thereby producing some of their side effects. In contrast, the tolerability and potential therapeutic utility of H1R agonism is currently unclear. We have used a cell-based functional assay to evaluate known therapeutics and reference drugs for H1R agonist activity. Our initial functional screen identified three ergot-based compounds possessing heretofore-unknown H1R agonist activity. 8R-lisuride demonstrated potent agonist activity in various assays including receptor selection and amplification technology, inositol phosphate acc uMulation, and activation of nuclear factor-kappaB with pEC50 values of 8.1, 7.9, and 7.9, respectively, and with varying degrees of efficacy. Based on these assays, 8R-lisuride is the most potent stereospecific partial agonist for the h uMan H1R yet reported. Investigation of the residues involved in histamine and lisuride binding, using H1R mutants and molecular modeling, have revealed that although these ligands are structurally different, the lisuride-binding pocket in the H1R closely corresponds to the histamine-binding pocket. The discovery of a potent stereospecific partial H1R agonist provides a valuable tool to further characterize this important therapeutic target in vitro. | [535914] | Drug Info | ||
References | |||||
Ref 553130 | The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro. Br J Clin Pharmacol. 1986 Nov;22(5):535-40. | ||||
Ref 533759 | J Med Chem. 1995 Jan 20;38(2):318-27.Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands. | ||||
Ref 533515 | J Med Chem. 1982 Oct;25(10):1133-40.Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. | ||||
Ref 529191 | Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. Epub 2007 Nov 17.Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. | ||||
Ref 533512 | J Med Chem. 1980 Jun;23(6):635-43.Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. | ||||
Ref 527160 | J Med Chem. 2004 Aug 12;47(17):4155-8.Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 receptor selectivity. | ||||
Ref 531079 | J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. | ||||
Ref 528099 | Bioorg Med Chem Lett. 2006 Jun 1;16(11):2955-9. Epub 2006 Mar 24.Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. | ||||
Ref 529541 | Bioorg Med Chem. 2008 Jul 15;16(14):6675-81. Epub 2008 Jun 5.Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. | ||||
Ref 529541 | Bioorg Med Chem. 2008 Jul 15;16(14):6675-81. Epub 2008 Jun 5.Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. | ||||
Ref 535914 | 8R-lisuride is a potent stereospecific histamine H1-receptor partial agonist. Mol Pharmacol. 2004 Mar;65(3):538-49. | ||||
Ref 529238 | Bioorg Med Chem. 2008 Mar 15;16(6):3218-23. Epub 2007 Dec 31.Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. | ||||
Ref 529371 | J Med Chem. 1991 Oct;34(10):2946-53.Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands. | ||||
Ref 533570 | J Med Chem. 1982 Jul;25(7):855-8.Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. | ||||
Ref 525759 | J Nat Prod. 2000 Apr;63(4):480-4.Halogenated boldine derivatives with enhanced monoamine receptor selectivity. | ||||
Ref 528616 | J Med Chem. 2007 Jan 25;50(2):171-81.Advances in development of dopaminergic aporphinoids. | ||||
Ref 528616 | J Med Chem. 2007 Jan 25;50(2):171-81.Advances in development of dopaminergic aporphinoids. | ||||
Ref 525759 | J Nat Prod. 2000 Apr;63(4):480-4.Halogenated boldine derivatives with enhanced monoamine receptor selectivity. | ||||
Ref 533481 | J Med Chem. 1986 Oct;29(10):1904-12.Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. | ||||
Ref 533481 | J Med Chem. 1986 Oct;29(10):1904-12.Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. | ||||
Ref 529686 | Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. Epub 2008 Aug 28.N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. | ||||
Ref 529289 | J Med Chem. 2008 Feb 28;51(4):983-7. Epub 2008 Feb 6.Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity. | ||||
Ref 529289 | J Med Chem. 2008 Feb 28;51(4):983-7. Epub 2008 Feb 6.Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity. | ||||
Ref 530404 | J Med Chem. 1990 Nov;33(11):2948-50.(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. | ||||
Ref 530404 | J Med Chem. 1990 Nov;33(11):2948-50.(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. | ||||
Ref 528616 | J Med Chem. 2007 Jan 25;50(2):171-81.Advances in development of dopaminergic aporphinoids. | ||||
Ref 529734 | J Med Chem. 2008 Nov 13;51(21):6829-38. Epub 2008 Oct 4.Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. | ||||
Ref 533481 | J Med Chem. 1986 Oct;29(10):1904-12.Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. | ||||
Ref 529289 | J Med Chem. 2008 Feb 28;51(4):983-7. Epub 2008 Feb 6.Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity. | ||||
Ref 529289 | J Med Chem. 2008 Feb 28;51(4):983-7. Epub 2008 Feb 6.Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity. | ||||
Ref 525759 | J Nat Prod. 2000 Apr;63(4):480-4.Halogenated boldine derivatives with enhanced monoamine receptor selectivity. | ||||
Ref 527264 | Bioorg Med Chem Lett. 2004 Dec 6;14(23):5813-6.Design, synthesis, and evaluation of hexahydrobenz[f]isoquinolines as a novel class of dopamine 3 receptor ligands. | ||||
Ref 533332 | J Med Chem. 1989 Aug;32(8):1913-21.Synthesis and receptor affinities of some conformationally restricted analogues of the dopamine D1 selective ligand (5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl- 1H-3-benzazepin-7-ol. | ||||
Ref 530558 | Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. Epub 2009 Nov 20.Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. | ||||
Ref 525773 | J Med Chem. 2000 May 18;43(10):2079-81.7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for dopamine receptor antagonists. | ||||
Ref 528616 | J Med Chem. 2007 Jan 25;50(2):171-81.Advances in development of dopaminergic aporphinoids. | ||||
Ref 527160 | J Med Chem. 2004 Aug 12;47(17):4155-8.Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 receptor selectivity. | ||||
Ref 533481 | J Med Chem. 1986 Oct;29(10):1904-12.Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. | ||||
Ref 529850 | Bioorg Med Chem Lett. 2009 Jan 1;19(1):51-3. Epub 2008 Nov 13.Synthesis and neuropharmacological evaluation of esters of R(-)-N-alkyl-11-hydroxy-2-methoxynoraporphines. | ||||
Ref 533481 | J Med Chem. 1986 Oct;29(10):1904-12.Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. | ||||
Ref 533416 | J Med Chem. 1988 Oct;31(10):1941-6.Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands. | ||||
Ref 529011 | Bioorg Med Chem. 2007 Nov 1;15(21):6819-29. Epub 2007 Aug 19.In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine receptors. | ||||
Ref 534738 | J Med Chem. 1998 Nov 5;41(23):4486-91.Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes. | ||||
Ref 533577 | J Med Chem. 1981 Sep;24(9):1021-6.Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. | ||||
Ref 534719 | J Med Chem. 1998 Oct 8;41(21):4165-70.N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies. | ||||
Ref 528876 | Bioorg Med Chem Lett. 2007 Aug 1;17(15):4128-30. Epub 2007 May 23.R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands. | ||||
Ref 533481 | J Med Chem. 1986 Oct;29(10):1904-12.Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. | ||||
Ref 552866 | Dopamine D5 receptors: a challenge to medicinal chemists. Mini Rev Med Chem. 2008 Sep;8(10):976-95. | ||||
Ref 530342 | J Med Chem. 1990 Jun;33(6):1800-5.Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues. | ||||
Ref 529349 | Bioorg Med Chem. 2008 Apr 15;16(8):4563-8. Epub 2008 Feb 15.Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. | ||||
Ref 529289 | J Med Chem. 2008 Feb 28;51(4):983-7. Epub 2008 Feb 6.Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity. | ||||
Ref 529289 | J Med Chem. 2008 Feb 28;51(4):983-7. Epub 2008 Feb 6.Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity. | ||||
Ref 525629 | Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. | ||||
Ref 529349 | Bioorg Med Chem. 2008 Apr 15;16(8):4563-8. Epub 2008 Feb 15.Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. | ||||
Ref 529349 | Bioorg Med Chem. 2008 Apr 15;16(8):4563-8. Epub 2008 Feb 15.Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. | ||||
Ref 529734 | J Med Chem. 2008 Nov 13;51(21):6829-38. Epub 2008 Oct 4.Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. | ||||
Ref 527714 | J Med Chem. 2005 Sep 8;48(18):5771-9.Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists. | ||||
Ref 527160 | J Med Chem. 2004 Aug 12;47(17):4155-8.Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 receptor selectivity. | ||||
Ref 525629 | Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. | ||||
Ref 534656 | J Nat Prod. 1998 Jun 26;61(6):709-12.Synthesis and dopamine receptor selectivity of the benzyltetrahydroisoquinoline, (R)-(+)-nor-roefractine. | ||||
Ref 525759 | J Nat Prod. 2000 Apr;63(4):480-4.Halogenated boldine derivatives with enhanced monoamine receptor selectivity. | ||||
Ref 530404 | J Med Chem. 1990 Nov;33(11):2948-50.(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. | ||||
Ref 528616 | J Med Chem. 2007 Jan 25;50(2):171-81.Advances in development of dopaminergic aporphinoids. | ||||
Ref 528616 | J Med Chem. 2007 Jan 25;50(2):171-81.Advances in development of dopaminergic aporphinoids. | ||||
Ref 528616 | J Med Chem. 2007 Jan 25;50(2):171-81.Advances in development of dopaminergic aporphinoids. | ||||
Ref 525759 | J Nat Prod. 2000 Apr;63(4):480-4.Halogenated boldine derivatives with enhanced monoamine receptor selectivity. | ||||
Ref 529349 | Bioorg Med Chem. 2008 Apr 15;16(8):4563-8. Epub 2008 Feb 15.Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. | ||||
Ref 533578 | J Med Chem. 1981 Sep;24(9):1107-10.Synthesis and evaluation of 1,2,3,4-tetrahydro[1]benzothieno[2,3-h]isoquinolines as dopamine antagonists. | ||||
Ref 553248 | D1 dopamine receptor activity of anti-parkinsonian drugs. Life Sci. 1997;60(18):1597-603. | ||||
Ref 534532 | J Med Chem. 1997 Dec 5;40(25):4146-53.Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. | ||||
Ref 529686 | Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. Epub 2008 Aug 28.N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. | ||||
Ref 529686 | Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. Epub 2008 Aug 28.N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. | ||||
Ref 529686 | Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. Epub 2008 Aug 28.N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. | ||||
Ref 529686 | Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. Epub 2008 Aug 28.N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. | ||||
Ref 527160 | J Med Chem. 2004 Aug 12;47(17):4155-8.Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 receptor selectivity. | ||||
Ref 530374 | Bioorg Med Chem. 2009 Oct 1;17(19):6898-907. Epub 2009 Aug 20.Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities?. | ||||
Ref 527160 | J Med Chem. 2004 Aug 12;47(17):4155-8.Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 receptor selectivity. | ||||
Ref 527160 | J Med Chem. 2004 Aug 12;47(17):4155-8.Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 receptor selectivity. | ||||
Ref 525629 | Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. | ||||
Ref 530341 | J Med Chem. 1990 Jun;33(6):1756-64.trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.